Intra-cellular Therapies Stock Fair Value Calculation – Avidity Partners Management LP Reduces Holdings in Intra-Cellular Therapies,
June 25, 2023
🌥️Trending News
INTRA-CELLULAR ($NASDAQ:ITCI): Avidity Partners Management LP has recently decreased their stake in Intra-Cellular Therapies, Inc. at Defense World. Intra-Cellular Therapies, Inc. is biopharmaceutical company focused on the discovery and development of novel, small molecule drugs that target intracellular signaling pathways for the treatment of neuropsychiatric and neurological diseases. The company’s lead drug candidate is lumateperone, which is in clinical development for the treatment of schizophrenia, bipolar disorder, agitation associated with dementia, and behavioral disturbances in patients with Parkinson’s disease. The company also has programs in the preclinical stage for cognition, mood disorders, and the treatment of gastrointestinal disorders.
Intra-Cellular Therapies, Inc. is traded on the Nasdaq Global Select Market under the ticker symbol ITCI. The company’s vision is to bring innovative treatments to patients with neuropsychiatric and neurological diseases that are underserved and have high unmet needs. They are committed to developing targeted therapies to improve the lives of these patients and their families.
Share Price
Intra-Cellular Therapies, Inc. saw a decrease of 1.0% in their stock prices on Wednesday. The stock opened at $65.0 and closed at $64.4, lower than the previous closing price of $65.0. This reduced demand for the stock drove the price down. In response to the news, investors responded with caution. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Intra-cellular Therapies. More…
| Total Revenues | Net Income | Net Margin |
| 309.11 | -228.19 | -73.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Intra-cellular Therapies. More…
| Operations | Investing | Financing |
| -247.4 | 177.2 | 16.98 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Intra-cellular Therapies. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 722.16 | 94.55 | 6.56 |
Key Ratios Snapshot
Some of the financial key ratios for Intra-cellular Therapies are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 589.5% | – | -77.4% |
| FCF Margin | ROE | ROA |
| -80.1% | -23.3% | -20.7% |
Analysis – Intra-cellular Therapies Stock Fair Value Calculation
GoodWhale recently conducted a fundamental analysis of INTRA-CELLULAR THERAPIES to determine its fair value. Using our proprietary Valuation Line, we determined that the fair value of INTRA-CELLULAR THERAPIES stock is approximately $166.9. However, the current market price for INTRA-CELLULAR THERAPIES is only $64.4 – this means the stock is undervalued by 61.4%. We believe that investors could take advantage of this discrepancy and acquire INTRA-CELLULAR THERAPIES stock at a substantial discount. More…
Peers
The company’s lead product candidate, lumateperone, is in Phase III clinical trials for the treatment of schizophrenia. SCYNEXIS Inc, Invion Ltd, and Shuttle Pharmaceuticals Holdings Inc are all clinical stage biopharmaceutical companies that focus on the development of small molecule drugs for the treatment of neuropsychiatric disorders.
– SCYNEXIS Inc ($NASDAQ:SCYX)
SCYNEXIS Inc is a biopharmaceutical company that focuses on the development and commercialization of oral and intravenous anti-infective agents to treat patients with serious and life-threatening infections. The company’s lead product, SCY-078, is a novel, first-in-class oral and intravenous agent in clinical development for the treatment of serious fungal infections. The company’s second product, SCY-123, is an oral agent in clinical development for the treatment of bacterial infections, including Clostridium difficile infection.
– Invion Ltd ($ASX:IVX)
Invion Ltd is a development stage biopharmaceutical company, which focuses on the treatment of cancer and inflammatory disease. The company was founded in 2003 and is headquartered in Brisbane, Australia.
– Shuttle Pharmaceuticals Holdings Inc ($NASDAQ:SHPH)
Shuttle Pharmaceuticals Holdings Inc is a pharmaceutical company with a market cap of 25.81M as of 2022. The company has a Return on Equity of 47.66%. Shuttle Pharmaceuticals Holdings Inc is engaged in the research, development, manufacture, and sale of pharmaceutical products. The company’s products include prescription and over-the-counter drugs, as well as nutritional supplements and other health-related products.
Summary
Avidity Partners Management LP has recently reduced its stake in Intra-Cellular Therapies, Inc. (ICT), a biopharmaceutical company focused on the development of novel treatments for neuropsychiatric and neurodegenerative diseases. Given the current difficult market conditions, ICT’s stock price has dropped significantly, potentially making it an attractive investment opportunity for investors willing to take on additional risk. Analysts assert that the company has a strong pipeline of promising treatments and the potential for long-term growth, making ICT a potential value play.
Additionally, ICT has a number of partnerships with major companies which could help drive future revenue growth. Investors should carefully consider the potential risks associated with investing in ICT, such as the volatility of the biopharmaceutical sector, the limited success rate of new treatments, and the limited financial resources available to the company compared to its competitors.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
